Equities

Profile data is unavailable for this security.

About the company

Johnson & Johnson is a holding company, which is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. It operates through three segments: Consumer, Pharmaceutical and Medical Devices. Its primary focus is products related to human health and well-being. The Consumer segment includes a range of products used in the baby care, oral care, skin care, over-the-counter pharmaceutical, women's health and wound care markets. The Pharmaceutical segment is focused on five therapeutic areas, including immunology, infectious diseases, neuroscience, oncology, and cardiovascular and metabolic diseases. The Medical Devices segment includes a range of products used in the orthopedic, surgery, cardiovascular, diabetes care and vision care fields. Its research facilities are located in the United States, Belgium, Brazil, Canada, China, France, Germany, India, Israel, Japan, the Netherlands, Singapore, Switzerland and the United Kingdom.

  • Revenue in USD (TTM)81.33bn
  • Net income in USD16.33bn
  • Incorporated1887
  • Employees135.10k
  • Location
    Johnson & Johnson1 Johnson And Johnson PlzNEW BRUNSWICK 08933-0001United StatesUSA
  • Phone+1 (732) 524-2455
  • Fax+1 (732) 214-0332
  • Websitehttps://www.jnj.com/
More ▼

Mergers & acquisitions

Acquired companyDeal statusDateDate /
Deal status
JNJ:NYQ since
announced
Transaction
value
Innovalens BVDeal completed15 Feb 201915 Feb 2019Deal completed-1.82%--
CIC CorpDeal completed23 Oct 201823 Oct 2018Deal completed-4.92%711.33m
Ci:z Holdings Co LtdDeal completed23 Oct 201823 Oct 2018Deal completed-4.92%1.33bn
EIT Emerging Implant Technologies GmbHAnnounced31 Aug 201831 Aug 2018Announced-2.29%--
Data delayed at least 15 minutes, as of Jul 17 2019 21:00 BST.

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Bristol-Myers Squibb Co23.29bn5.17bn72.18bn23.30k13.974.7412.193.103.163.1414.239.300.68585.355.19999,485.0015.2910.0521.0813.9271.1373.8722.2917.901.7928.850.28274.948.596.6127.4914.1912.112.71
Gilead Sciences, Inc.22.32bn5.90bn85.09bn11.00k14.753.8811.623.814.544.5417.2017.230.34825.396.322,029,091.009.1923.0810.9228.2278.4584.3726.4043.523.5310.790.546117.01-15.2414.59-46.0612.1737.10--
AbbVie Inc32.65bn5.42bn101.00bn30.00k19.32--13.883.093.543.4821.58-5.290.51784.315.671,088,233.008.649.3011.4512.1277.3177.2416.6818.820.91425.261.2783.7616.0811.751.066.835.3817.54
Eli Lilly And Co23.95bn2.75bn103.97bn38.68k39.5041.9224.234.342.716.2823.582.550.58151.564.95619,128.806.686.489.269.0074.9674.0111.4911.690.849329.720.861687.087.361.2299.27-6.1722.522.80
Amgen, Inc.23.75bn8.08bn108.00bn21.50k14.1310.0410.754.5512.5312.5336.8817.630.35141.416.421,104,651.0011.959.9614.4211.4282.2781.1534.0032.602.5313.020.75340.323.934.923.9010.561.2722.94
Merck & Co., Inc.43.07bn8.76bn210.91bn69.00k24.757.6816.294.903.313.1716.2410.660.51162.405.80624,246.4010.306.6813.088.3569.0666.2120.1315.621.0642.450.483481.415.41-0.802629.698.1311.062.96
Pfizer Inc.53.86bn10.67bn237.63bn92.40k23.674.0413.934.411.811.959.1810.580.33661.365.65582,889.606.695.418.156.5079.5779.4219.8717.731.2731.440.432881.632.100.7874-13.10-1.888.437.21
Johnson & Johnson81.33bn16.33bn350.10bn135.10k21.87--21.954.306.036.0330.00--------601,961.50--11.03--13.7266.8168.4320.0820.80--199.64--55.226.712.736.972.040.41386.45
Data as of Jul 17 2019. Currency figures normalised to Johnson & Johnson's reporting currency: US Dollar USD

Institutional shareholders

26.88%Per cent of shares held by top holders
HolderShares% Held
The Vanguard Group, Inc.as of 31 Mar 2019219.81m8.28%
SSgA Funds Management, Inc.as of 31 Mar 2019155.14m5.84%
BlackRock Fund Advisorsas of 31 Mar 2019128.54m4.84%
State Farm Investment Management Corp.as of 31 Mar 201937.88m1.43%
Geode Capital Management LLCas of 31 Mar 201935.84m1.35%
Northern Trust Investments, Inc.(Investment Management)as of 31 Mar 201934.94m1.32%
Massachusetts Financial Services Co.as of 31 Mar 201928.15m1.06%
Norges Bank Investment Managementas of 31 Dec 201827.01m1.02%
Wellington Management Co. LLPas of 31 Mar 201923.90m0.90%
Capital Research & Management Co. (International Investors)as of 31 Mar 201922.61m0.85%
More ▼
Data from 31 Dec 2018 - 31 Mar 2019Source: FactSet Research Systems Inc.
The Financial and Risk business of Thomson Reuters is now Refinitiv
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.